Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Pancreatology ; 17(1): 139-145, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28027897

RESUMO

BACKGROUND: Chemotherapy with 5-FU and Streptozotocin (STZ) is recommended as first-line treatment in patients with metastatic pancreatic neuroendocrine neoplasms (PNEN). However, data about biomarkers involved in the 5-FU metabolism to predict response are still limited. OBJECTIVES: Evaluation of clinicopathological features and potential predictive and prognostic markers of patients with PNEN treated with 5-FU based regimens. PATIENTS AND METHODS: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013. Dihydropyrimidine-Dehydrogenase (DPD) and Thymidylate-Synthase (TS) expression was correlated with treatment response in 19 patients who had available tumour tissue and response data. The median overall survival (OS) and progression free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively. RESULTS: The median PFS in patients receiving 5-FU/STZ was 17 months with a median OS of 50 months. Objective response rate (ORR) and disease control rate (DCR) were 32% and 73%, respectively. Biochemical response (p = 0.005) and high DPD expression (p = 0.018) were predictive markers of response to 5-FU-based chemotherapy. Univariate analysis identified Ki-67 > 10%, no biochemical response, positive 5-HIAA levels and TS deficiency as independent risk factors for shorter PFS. Moreover, performance status (PS) ≥1 was an independent risk factors for impaired OS. CONCLUSIONS: DPD expression and biochemical response represent promising predictive biomarkers for response to 5-FU based chemotherapy. Moreover, Ki-67, PS and TS are independent prognostic markers of OS and PFS in patients with PNEN.


Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Di-Hidrouracila Desidrogenase (NADP)/metabolismo , Fluoruracila/uso terapêutico , Tumores Neuroendócrinos/tratamento farmacológico , Neoplasias Pancreáticas/tratamento farmacológico , Timidilato Sintase/metabolismo , Adulto , Idoso , Biomarcadores Tumorais/metabolismo , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Tumores Neuroendócrinos/enzimologia , Tumores Neuroendócrinos/mortalidade , Neoplasias Pancreáticas/enzimologia , Neoplasias Pancreáticas/mortalidade , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento
2.
Phys Ther ; 63(12): 1988-91, 1983 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-6647554

RESUMO

Deficits in sensorimotor integration, cognition, and psychosocial behavior may lead to a characteristic set of problems in the head-injured adult. An inpatient Sensorimotor Integration Class for ambulatory head-injured patients was developed to introduce challenging sensorimotor activities before these patients established avoidance patterns. The class includes perceptual motor, sensory integration, and sports activities. Clinical observations suggest that the class leads to improved quality of movement for participants. Objective research is needed to document clinical observations.


Assuntos
Lesões Encefálicas/reabilitação , Terapia por Exercício/métodos , Transtornos dos Movimentos/reabilitação , Transtornos da Percepção/reabilitação , Adulto , Lesões Encefálicas/complicações , Humanos , Transtornos dos Movimentos/etiologia , Transtornos da Percepção/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA